title: Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
abstract: Effective treatments for malignant neuroendocrine tumors are under development. While iodine-131 metaiodobenzylguanidine (¹³¹I-MIBG) radiotherapy has been used in the treatment of malignant neuroendocrine tumors, there are few studies evaluating its therapeutic effects and safety in a multicenter cohort. In the current study, we sought to evaluate the effects and safety of ¹³¹I-MIBG therapy for conditions including malignant pheochromocytoma and paraganglioma within a multicenter cohort. Forty-eight malignant neuroendocrine tumors (37 pheochromocytoma and 11 paraganglioma) from four centers underwent clinical ¹³¹I-MIBG radiotherapy. The tumor responses were observed before and 3 to 6 months after the ¹³¹I-MIBG radiotherapy in accordance with RECIST criteria. We also evaluated the data for any adverse effects. The four centers performed a total of 87 ¹³¹I-MIBG treatments on 48 patients between January 2000 and March 2009. Of the treatments, 65 were evaluable using RECIST criteria. One partial response (PR), 40 stable disease (SD), and 9 progressive disease (PD) in malignant pheochromocytoma were observed after each treatment. Fourteen SD and one PD-were observed in paraganglioma. Patients with normal hypertension (systolic blood pressure (BP) > 130 mmHg) showed significantly reduced systolic BP after the initial follow-up (n=10, 138.1±8.2 to 129.5±13.5 mmHg, P=0.03). In adult neuroendocrine tumors with a treatment-basis analysis, there were side effects following 41 treatments (47.1%) and most of them (90.2%) were minor. In this multicenter registry, PR or SD was achieved in 84.6% of the treatment occasions in adult neuroendocrine tumors through ¹³¹I-MIBG radiotherapy. This indicated that most of the ¹³¹I-MIBG radiotherapy was performed safely without significant side effects.
authors.affiliation: Department of Molecular Imaging, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Yoshinaga
authors.forename: Noboru
authors.initials: N
authors.lastname: Oriuchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Wakabayashi
authors.forename: Yuuki
authors.initials: Y
authors.lastname: Tomiyama
authors.forename: Megumi
authors.initials: M
authors.lastname: Jinguji
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Higuchi
authors.forename: Daiki
authors.initials: D
authors.lastname: Kayano
authors.forename: Makoto
authors.initials: M
authors.lastname: Fukuoka
authors.forename: Anri
authors.initials: A
authors.lastname: Inaki
authors.forename: Ayane
authors.initials: A
authors.lastname: Toratani
authors.forename: Shozo
authors.initials: S
authors.lastname: Okamoto
authors.forename: Tohru
authors.initials: T
authors.lastname: Shiga
authors.forename: Yoichi M
authors.initials: YM
authors.lastname: Ito
authors.forename: Masatoyo
authors.initials: M
authors.lastname: Nakajo
authors.forename: Masayuki
authors.initials: M
authors.lastname: Nakajo
authors.forename: Seigo
authors.initials: S
authors.lastname: Kinuya
mesh_terms: D019797:3-Iodobenzylguanidine / Q000009:adverse effects / Q000627:therapeutic use*; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000532:radiotherapy*; D000311:Adrenal Glands / Q000000981:diagnostic imaging / Q000378:metabolism / Q000528:radiation effects; D000328:Adult; D000368:Aged; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006785:Hospitals, University; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D007564:Japan; D008297:Male; D008875:Middle Aged; D010235:Paraganglioma / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology / Q000532:radiotherapy*; D010673:Pheochromocytoma / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology / Q000532:radiotherapy*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D012042:Registries
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine